左西孟旦在左室功能减低患者行单纯冠脉或瓣膜手术中的疗效与费用分析
该研究为LEVO-CTS试验的预设分析,按手术类型比较左西孟旦与安慰剂的效果与费用。共563例(66.4%)行单纯CABG,97例(11.4%)行单纯瓣膜,188例(22.2%)行CABG联合瓣膜手术。结果显示左西孟旦在单纯CABG患者中降低90天死亡率和低心排综合征,但在瓣膜或联合手术中未见显著获益。
要点
- 单纯CABG患者中左西孟旦降低90天死亡率(2.1% vs 7.9%;HR 0.26;95%CI 0.11-0.64)。
- 单纯CABG患者中左西孟旦降低低心排综合征发生率(12.0% vs 22.1%;OR 0.48;95%CI 0.30-0.76)。
- 瓣膜或联合手术患者中左西孟旦未见显著临床获益。
核心结论
- 左西孟旦在单纯CABG患者中与较低的90天死亡率和低心排综合征相关,但在单纯瓣膜或CABG联合瓣膜手术中未观察到显著差异。
研究设计与样本
- LEVO-CTS试验的预设分析,比较不同心脏手术类型中左西孟旦与安慰剂的治疗相关结局和费用。
主要发现
- 4组分和2组分复合结局在CABG、瓣膜或联合手术中左西孟旦与安慰剂均无显著差异。
- 排除研究药物费用后,30天中位和平均费用左西孟旦组为53,707美元和65,852美元,安慰剂组为54,636美元和67,122美元,30天平均差异为-1,270美元(bootstrap 95%CI,-8,722至6,165美元)。
临床怎么用
- 对于行单纯CABG的左室功能减低患者,左西孟旦可能降低90天死亡率和低心排综合征风险。
- 在单纯瓣膜或CABG联合瓣膜手术患者中,左西孟旦未显示显著临床获益,需个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial, no differences in clinical outcomes were observed between levosimendan and placebo in a broad population of patients undergoing cardiac surgery. In previous studies, the benefits of levosimendan were most clearly evident in patients undergoing isolated coronary artery bypass grafting (CABG) surgery. In a prespecified analysis of LEVO-CTS, we compared treatment-related outcomes and costs across types of cardiac surgical procedures. METHODS: Overall, 563 (66.4%) patients underwent isolated CABG, 97 (11.4%) isolated valve, and 188 (22.2%) combined CABG/valve surgery. Outcomes included the co-primary 4-component composite (30-day mortality, 30-day renal replacement, 5-day myocardial infarction, or 5-day mechanical circulatory support), the 2-component composite (30-day mortality or 5-day mechanical circulatory support), 90-day mortality, low cardiac output syndrome (LCOS), and 30-day medical costs. RESULTS: The 4- and 2-component outcomes were not significantly different with levosimendan and placebo in patients undergoing CABG (15.2% vs 19.3% and 7.8% vs 10.4%), valve (49.0% vs 33.3% and 22.4% vs 2.1%), or combined procedures (39.6% vs 35.9% and 24.0% vs 19.6%). Ninety-day mortality was lower with levosimendan in isolated CABG (2.1% vs 7.9%; hazard ratio [HR], 0.26; 95% confidence interval [CI], 0.11-0.64), but not significantly different in valve (8.3% vs 2.0%; HR, 4.10; 95% CI, 0.46-36.72) or combined procedures (10.4% vs 7.6%; HR, 1.39; 95% CI, 0.53-3.64; interaction P = .011). LCOS (12.0% vs 22.1%; odds ratio, 0.48; 95% CI, 0.30-0.76; interaction P = .118) was significantly lower in levosimendan-treated patients undergoing isolated CABG. Excluding study drug costs, median and mean 30-day costs were $53,707 and $65,852 for levosimendan and $54,636 and $67,122 for placebo, with a 30-day mean difference (levosimendan - placebo) of -$1270 (bootstrap 95% CI, -$8722 to $6165). CONCLUSIONS: Levosimendan was associated with lower 90-day mortality and LCOS in patients undergoing isolated CABG, but not in those undergoing isolated valve or combined CABG/valve procedures.
引用
- van Diepen S, Mehta RH, Leimberger JD, et al. Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. J Thorac Cardiovasc Surg. 2019. PMID: 31358329. doi:10.1016/j.jtcvs.2019.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。